Drug Trial Radar · NCT04234204
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause
Last checked: Nov 20, 2026Latest source record: Jan 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
302
Actual
Start
Mar 17, 2020
Primary completion
Apr 20, 2022
Study completion Apr 20, 2022
Sponsor
- Lead sponsor
- Astellas Pharma China, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jan 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 40 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is for women in menopause with moderate to severe hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life. The study treatments are fezolinetant (1 tablet) once a day or placebo (1 tablet) once a day. (Placebo is a dummy treatment that looks like medicine but does not have any medicine in it.) The study will compare fezolinetant and placebo after 4 and 12 weeks of dosing. The study will see if fezolinetant reduces the number of hot flashes. And the study will see if fezolinetant reduces the severity of the hot flashes. Women in the study will receive an electronic handheld device at the first study visit. (It is similar to a smart phone.) Each day of the study, study participants will use this to record their hot flashes. Their record for the 10 days before the start of study treatment will be checked. They can remain in the study if their record shows 7 or 8 moderate to severe hot flashes per day (50 or more per week). Next, they will be picked for 1 of the 2 study treatments (fezolinetant or placebo) by chance alone. It is like flipping a coin. The study participants will take study treatment for 24 weeks. The first 12 weeks of study treatment are "double-blinded." That means that the study participants and the study doctors do not know who takes which of the study treatments (fezolinetant or placebo) during that time. The last 12 weeks of study treatment are "noncontrolled." That means that each study participant and the study doctors know which study treatment that study participant takes during that time. Women who take fezolinetant during the first 12 weeks will continue to take fezolinetant. Women who take placebo during the first 12 weeks will start taking fezolinetant. At weeks 2, 4, 8, 12, 14, 16, 20 and 24, the study participants will go to the hospital or clinic for a check-up. They will be asked about medications, side effects and how they feel. Other checks will include physical exam and vital signs (heart rate, temperature and blood pressure). Blood and urine will be collected for laboratory tests. Study participants will complete questionnaires that are about how hot flashes affect their daily life. Study participants who still have their uterus will have the following 2 tests done at the first and last study visits if they meet the criteria. One of the 2 tests is endometrial biopsy. This test involves removing a small amount of tissue from the inside lining of the uterus. The tissue is then checked under a microscope. The other test is transvaginal ultrasound. This test uses sound waves to create pictures of the organs in the pelvis. The sound waves are transmitted by a probe (transducer), which is placed inside the vagina. Study participants may have a screening mammogram done at the first and/or last study visit. A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study participants who did not have this test done in the last 12 months will have it done at the first study visit. They will have it done at the last study visit if they are due for their screening mammogram and their own doctor agrees. The last check-up at the hospital or clinic will be 3 weeks after the last dose of study treatment.
Conditions
- Hot Flashes
Interventions
FezolinetantDrug
Oral
PlaceboDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in the frequency of moderate to severe vasomotor symptoms (VMS)Time frame: Baseline to Week 4
- Mean change from baseline in the frequency of moderate to severe VMSTime frame: Baseline to Week 12
- Mean change from baseline in the severity of moderate to severe VMSTime frame: Baseline to Week 4
- Mean change from baseline in the severity of moderate to severe VMSTime frame: Baseline to Week 12
Locations
48 sites in 3 countries. Site status is shown where the registry gives one.
Site CN86001
Beijing, China
Site CN86002
Beijing, China
Site CN86017
Beijing, China
Site CN86030
Beijing, China
Site CN86022
Changchun, China
Site CN86009
Changsha, China
Site CN86037
Chengdu, China
Site CN86006
Guangzhou, China
Site CN86019
Guangzhou, China
Site CN86042
Guangzhou, China
Site CN86043
Guangzhou, China
Site CN86018
Guiyang, China
Site CN86025
Hangzhou, China
Site CN86034
Hangzhou, China
Site CN86027
Kunming, China
Site CN86005
Liuzhou, China
Site CN86004
Nanjing, China
Site CN86011
Nanjing, China
Site CN86035
Nanjing, China
Site CN86026
Nanning, China
Site CN86012
Shanghai, China
Site CN86021
Shenzhen, China
Site CN86007
Shijiazhuang, China
Site CN86023
Taiyuan, China
Site CN86031
Taiyuan, China
Site CN86015
Tianjin, China
Site CN86029
Tianjin, China
Site CN86008
Wuhan, China
Site CN86041
Yangzhou, China
Site CN86013
Yinchuan, China
Site CN86033
Zhongshan, China
Site KR82013
Ansan-si, South Korea
Site KR82005
Busan, South Korea
Site KR82003
Seongnam-si, South Korea
Site KR82011
Seongnam-si, South Korea
Site KR82001
Seoul, South Korea
Site KR82002
Seoul, South Korea
Site KR82004
Seoul, South Korea
Site KR82006
Seoul, South Korea
Site KR82012
Seoul, South Korea
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.